Medicus selects 200 µg SkinJect patch as lead dose in final Phase 2 skin cancer study report

PUBT · 3d ago
Medicus selects 200 µg SkinJect patch as lead dose in final Phase 2 skin cancer study report
  • Medicus posted an abridged final Phase 2 SkinJect Clinical Study Report for nodular basal cell carcinoma on Sept. 10, 2026.
  • Results were presented now via public posting; the full dataset was submitted for future presentation at a major scientific congress.
  • Final analysis supported the 200 µg D-MNA patch as the lead dose, with improving clearance over longer follow-up.
  • Safety profile was described as favorable, with all 90 patients completing the study without discontinuations.
  • Development focus shifts to FDA-authorized SKNJCT-005 in Gorlin syndrome, while seeking partners for a registrational nodular BCC program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100730PRIMZONEFULLFEED9824052) on September 10, 2026, and is solely responsible for the information contained therein.